|Dr. Jan G.J. van de Winkel||Co-Founder, Pres & CEO||2.77M||N/A||1961|
|Mr. Anthony Pagano||Exec. VP & CFO||937.37k||N/A||1978|
|Mr. Anthony Mancini||Exec. VP & COO||1.42M||N/A||1971|
|Mr. Peter Storm Kristensen||Director of Legal Lead Corp. & Non-Independent Director||62.49k||N/A||1975|
|Dr. Judith V. Klimovsky||Exec. VP & Chief Devel. Officer||1.12M||N/A||1958|
|Dr. Mijke Zachariasse Ph.D.||Director of Protein Production & Chemist and Non-Independent Director||62.49k||N/A||1974|
|Dr. Rima Bawarshi Nassar Ph.D.||VP, Head of Global Regulatory Affairs Â Oncology & Non-Independent Director||15.62k||N/A||1953|
|Mr. Peter Ros||Sr. Director of Fin. & Accounting||N/A||N/A||N/A|
|Mr. Andrew Carlsen||Sr. Director & Head of Investor Relations||N/A||N/A||N/A|
|Ms. Birgitte Stephensen M.Sc.||Sr. VP & Head of Global IPR and Legal||N/A||N/A||1961|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S’s ISS governance QualityScore as of 26 September 2021 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 6.